A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
Paul G. Richardson(Harvard University), Philippe Moreau(Centre National de la Recherche Scientifique), Akshanth R. Polepally(AbbVie (United States)), Zeena Salman(Revolution Medicines (United States)), Monica Motwani(AbbVie (United States)), Sudhir Penugonda(ClearMotion (United States)), Yunming Mu(Revolution Medicines (United States))
Cited by 3
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k